Death for life – The Leishmania parasite needs dead competitors to outwit the immune system
Researchers at the Paul-Ehrlich-Institut have found out how unicellular parasites succeed in tricking our immune system. To be successful, live and dead leishmania parasites must enter the host cells simultaneously. The dead Leishmania are degraded in the cell by means of a self-digestion mechanism (autophagy).
Precise gene transfer into therapy relevant cells after vector injection into blood
Therapeutic gene transfer is considered as a promising novel strategy to treat genetic disorders and cancer. So far, target cells are often isolated from patients for this purpose, and re-administered after gene transfer. In collaboration with colleagues from the Universities of Cologne and Zurich, researchers at the Paul-Ehrlich-Institut have succeeded in developing gene transfer vehicles that target the therapy relevant cell type directly in the organism.
The Paul-Ehrlich-Institut approves clinical trial with Ebola vaccine candidate
The first clinical phase I trial to be conducted in Germany with the candidate vaccine rVSV-ZEBOV will start within the next few weeks. The trial will enrol healthy adults, possibly including healthcare personnel involved in the care of Ebola patients in Germany or Africa, and investigate the potential benefit of the vaccine candidate as well as its risks.